menu search

SMMT / Summit Therapeutics: Not For Retail Investors

Summit Therapeutics: Not For Retail Investors
Summit Therapeutics Inc., backed by biotech billionaire Bob Duggan, has transitioned from developing antibiotics to becoming an oncology therapeutics developer. The company purchased the oncology asset Ivonescimab for nearly half a billion dollars and now has a market cap of over $1 billion. Summit plans to begin phase 3 trials for Ivonescimab in the U.S., but the Chinese clinical data may not hold much value. Read More
Posted: Sep 26 2023, 15:00
Author Name: Seeking Alpha
Views: 102428

SMMT News  

Summit Therapeutics: Not For Retail Investors

By Seeking Alpha
September 26, 2023

Summit Therapeutics: Not For Retail Investors

Summit Therapeutics Inc., backed by biotech billionaire Bob Duggan, has transitioned from developing antibiotics to becoming an oncology therapeutics more_horizontal

Why Shares of Summit Therapeutics Slumped on Tuesday

By The Motley Fool
May 16, 2023

Why Shares of Summit Therapeutics Slumped on Tuesday

Summit's cash position is worrying. The company only has one therapy in clinical trials. more_horizontal

Why Shares of Summit Therapeutics Soared This Week

By The Motley Fool
May 5, 2023

Why Shares of Summit Therapeutics Soared This Week

The company's current pipeline only includes two drugs. Summit Therapeutics' shares are up more than 93% over the past 12 months. more_horizontal

Summit Therapeutics: Another Billionaire Project That Isn't Going Anywhere

By Seeking Alpha
April 13, 2023

Summit Therapeutics: Another Billionaire Project That Isn't Going Anywhere

Summit Therapeutics is mostly owned by Bob Duggan, who made billions from selling Pharmacyclics. However, Pharmacyclics had something to sell. more_horizontal

Summit Therapeutics Inc. (SMMT) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 10, 2023

Summit Therapeutics Inc. (SMMT) Q4 2022 Earnings Call Transcript

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q4 2022 Results Conference Call March 9, 2023 9:00 AM ET Company Participants Dave Gancarz - SVP, Corporate St more_horizontal

Summit Therapeutics: Ivonescimab Deal Potential Mid-Term Growth Driver

By Seeking Alpha
January 27, 2023

Summit Therapeutics: Ivonescimab Deal Potential Mid-Term Growth Driver

Summit Therapeutics rallied hard off 52-week lows in December after its licensing deal for Ivonescimab was announced. Gains have extended into the new more_horizontal

Why Summit Therapeutics Shares Soared This Week

By The Motley Fool
December 30, 2022

Why Summit Therapeutics Shares Soared This Week

The clinical-stage biopharma stock has been rising all year. more_horizontal

Investing in Penny Stocks? 5 Basic Terms to Know

By PennyStocks
December 10, 2022

Investing in Penny Stocks? 5 Basic Terms to Know

Five must-know terms for investing in penny stocks The post Investing in Penny Stocks? 5 Basic Terms to Know  appeared first on Penny Stocks to Buy, more_horizontal


Search within

Pages Search Results: